Trial Profile
Sublingual and subcutaneous routes combined in a new approach to immunotherapy for house dust mite-allergic asthma or rhinitis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2011
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary) ; House dust mite allergy immunotherapy injection ALK Abello (Primary)
- Indications Allergic asthma; Perennial allergic rhinitis
- Focus Therapeutic Use
- 04 Aug 2011 New trial record